9-34649466-C-T

Variant summary

Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong

The NM_000155.4(GALT):​c.961C>T​(p.His321Tyr) variant causes a missense change. The variant allele was found at a frequency of 0.0000031 in 1,614,056 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).

Frequency

Genomes: 𝑓 0.000013 ( 0 hom., cov: 31)
Exomes 𝑓: 0.0000021 ( 0 hom. )

Consequence

GALT
NM_000155.4 missense

Scores

13
4
2

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:6U:2

Conservation

PhyloP100: 4.13
Variant links:
Genes affected
GALT (HGNC:4135): (galactose-1-phosphate uridylyltransferase) Galactose-1-phosphate uridyl transferase (GALT) catalyzes the second step of the Leloir pathway of galactose metabolism, namely the conversion of UDP-glucose + galactose-1-phosphate to glucose-1-phosphate + UDP-galactose. The absence of this enzyme results in classic galactosemia in humans and can be fatal in the newborn period if lactose is not removed from the diet. The pathophysiology of galactosemia has not been clearly defined. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 16 ACMG points.

PM1
In a hotspot region, there are 7 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 4 uncertain in NM_000155.4
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.97
PP5
Variant 9-34649466-C-T is Pathogenic according to our data. Variant chr9-34649466-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 25299.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
GALTNM_000155.4 linkuse as main transcriptc.961C>T p.His321Tyr missense_variant 10/11 ENST00000378842.8
GALTNM_001258332.2 linkuse as main transcriptc.634C>T p.His212Tyr missense_variant 8/9

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
GALTENST00000378842.8 linkuse as main transcriptc.961C>T p.His321Tyr missense_variant 10/111 NM_000155.4 P1P07902-1

Frequencies

GnomAD3 genomes
AF:
0.0000131
AC:
2
AN:
152186
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.0000483
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.00000795
AC:
2
AN:
251458
Hom.:
0
AF XY:
0.0000147
AC XY:
2
AN XY:
135902
show subpopulations
Gnomad AFR exome
AF:
0.0000615
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.0000327
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000205
AC:
3
AN:
1461870
Hom.:
0
Cov.:
31
AF XY:
0.00000138
AC XY:
1
AN XY:
727238
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0000252
Gnomad4 SAS exome
AF:
0.0000232
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
AF:
0.0000131
AC:
2
AN:
152186
Hom.:
0
Cov.:
31
AF XY:
0.0000134
AC XY:
1
AN XY:
74358
show subpopulations
Gnomad4 AFR
AF:
0.0000483
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.00
ExAC
AF:
0.00000824
AC:
1

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:6Uncertain:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase Pathogenic:4Uncertain:1
Likely pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsMar 18, 2024- -
Likely pathogenic, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesJun 05, 2021The GALT c.961C>T; p.His321Tyr variant (rs367543266) is reported in the literature in one compound heterozygote and one homozygote affected with galactosemia (Webb 2003, ARUP data). This variant is reported in ClinVar (Variation ID: 25299). This variant is only observed on two alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. The histidine at codon 321 is moderately conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.922). Based on available information, this variant is considered to be likely pathogenic. References: Webb AL et al. Verbal dyspraxia and galactosemia. Pediatr Res. 2003 Mar;53(3):396-402. PMID: 12595586. -
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpJul 17, 2024Variant summary: GALT c.961C>T (p.His321Tyr) results in a conservative amino acid change located in the Galactose-1-phosphate uridyl transferase, C-terminal domain (IPR005850) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251458 control chromosomes (gnomAD). c.961C>T has been reported in the literature in individuals affected with Galactosemia including homozygous individuals with classic galactosemia (example: Webb_2003, Mir_2022, Yuzyuk_2018). These data indicate that the variant is very likely to be associated with disease. In vitro and in vivo functional studies show that the variant resulted in reduced activity (Yuzyuk_2018). The following publications have been ascertained in the context of this evaluation (PMID: 12595586, 30172461, 27005423). ClinVar contains an entry for this variant (Variation ID: 25299). Based on the evidence outlined above, the variant was classified as pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpAug 29, 2023This sequence change replaces histidine, which is basic and polar, with tyrosine, which is neutral and polar, at codon 321 of the GALT protein (p.His321Tyr). This variant is present in population databases (rs367543266, gnomAD 0.007%). This missense change has been observed in individual(s) with galactosemia (PMID: 12595586, 30172461; Invitae). ClinVar contains an entry for this variant (Variation ID: 25299). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALT protein function. Experimental studies have shown that this missense change affects GALT function (PMID: 30172461). For these reasons, this variant has been classified as Pathogenic. -
Uncertain significance, flagged submissionclinical testingCounsylJan 08, 2018- -
GALT-related disorder Pathogenic:1
Pathogenic, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesApr 15, 2024The GALT c.961C>T variant is predicted to result in the amino acid substitution p.His321Tyr. This variant has been reported, in the homozygous state or heterozygous with a second rare GALT variant, in patients with galactosemia (Table 1, Webb et al. 2003. PubMed ID: 12595586; Table 2, Yuzyuk et al. 2018. PubMed ID: 30172461; Mir et al. 2023. doi: 10.1159/000528905). Additionally, we have observed this variant in the apparent homozygous state in two siblings with classic galactosemia (Internal Data, PreventionGenetics). The p.His321 amino acid has been reported to play a role in GALT enzyme Zn2+ binding, and the p.His321Tyr substitution is predicted to disrupt this metal binding (McCorvie et al. 2016. PubMed ID: 27005423). Additionally, the p.His321Tyr substitution was reported to reduce in vitro enzyme activity to 3.9% of wild-type (Yuzyuk et al. 2018. PubMed ID: 30172461). This variant is reported in 0.0062% of alleles in individuals of African descent in gnomAD. Based on the collective evidence, this variant is interpreted as pathogenic. -
not provided Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingMayo Clinic Laboratories, Mayo ClinicDec 21, 2022PP3, PP4, PM2, PM3, PS3 -
Galactosemia Uncertain:1
Uncertain significance, flagged submissionclinical testingNatera, Inc.Sep 21, 2018- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.40
BayesDel_addAF
Pathogenic
0.39
D
BayesDel_noAF
Pathogenic
0.51
CADD
Uncertain
24
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.96
.;D
Eigen
Pathogenic
0.87
Eigen_PC
Pathogenic
0.81
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Pathogenic
0.99
D;D
M_CAP
Pathogenic
0.44
D
MetaRNN
Pathogenic
0.97
D;D
MetaSVM
Pathogenic
0.99
D
MutationAssessor
Pathogenic
3.7
.;H
MutationTaster
Benign
1.0
D;D
PrimateAI
Pathogenic
0.84
D
PROVEAN
Uncertain
-2.8
D;D
REVEL
Pathogenic
0.92
Sift
Benign
0.089
T;T
Sift4G
Uncertain
0.056
T;T
Polyphen
1.0
.;D
Vest4
0.86
MutPred
0.91
.;Gain of catalytic residue at P325 (P = 0.1317);
MVP
0.99
MPC
0.35
ClinPred
0.96
D
GERP RS
5.3
Varity_R
0.88
gMVP
0.84

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs367543266; hg19: chr9-34649463; API